Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Bassil Dahiyat | M | 53 | 27 jaar | |
Nancy Valente | M | 66 | 2 jaar | |
Kevin Gorman | M | 66 | 7 jaar | |
Kurt Gustafson | M | 56 | 10 jaar | |
Jeffrey Hessekiel | M | 55 | 10 jaar | |
Dagmar Rosa-Bjorkeson | F | 60 | 5 jaar | |
Alan Garber | M | 68 | 19 jaar | |
Ellen Feigal | M | 69 | 6 jaar | |
Celia Eckert | F | 52 | 5 jaar | |
Alan Montgomery | M | 70 | 9 jaar | |
Richard Ranieri | M | 71 | 7 jaar | |
George Poste | M | 79 | 20 jaar | |
Jack Wyszomierski | M | 68 | 20 jaar | |
Patrick Haley | M | 48 | 14 jaar | |
David Szymkowski | M | 60 | 22 jaar | |
Charles Liles | M | - | - | |
Jeremy Grunstein | M | - | 5 jaar | |
Barbara Klencke | M | 66 | 1 jaar | |
Raphael Clynes | M | - | 7 jaar | |
Laura Dillard | F | - | 19 jaar | |
Dane Leone | M | - | - | |
John Desjarlais | M | 59 | 23 jaar | |
Jennifer Sandoz | F | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Harold E. van Wart | M | 76 | 17 jaar | |
Laurence P. Birch | M | 64 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 4 jaar |
Louis Lange | M | 72 | 12 jaar | |
Edward Penhoet | M | 83 | 11 jaar | |
Jennifer Drimmer | F | - | 14 jaar | |
Carl Feldbaum | M | 80 | 16 jaar | |
Robert J. Weiland | M | 64 | 4 jaar | |
Martin K. McCarthy | M | 65 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
Evan Stein | M | 77 | 4 jaar | |
James Bucher | M | 59 | 7 jaar | |
Caroline Loewy | F | 58 | 8 jaar | |
Acquilar Rahman | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 21 jaar |
Ronald E. Pauli | M | 63 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 jaar |
Lawrence Kenyon | M | 58 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 6 jaar |
Guillermo A. Herrera | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 2 jaar |
Christoph Pereira | M | 51 | 3 jaar | |
Francis McCormick | M | 73 | 11 jaar | |
Paul Truex | M | 55 | 5 jaar | |
Robert Booth | M | 70 | 4 jaar | |
Ronald G. Eidell | M | 80 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
F. Michael Yakes | M | - | 11 jaar | |
Jeff P. Coon | M | 61 | 1 jaar | |
Anne Borgman | M | 56 | 7 jaar | |
John Nuss | M | 65 | 11 jaar | |
Gregory P. Young | M | 70 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 jaar |
Zafeer Ahmad | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
Larry Mattheakis | M | 67 | 4 jaar | |
Rekha Hemrajani | F | 54 | 8 jaar | |
Nancy M. Wyant | F | - |
BeiGene USA, Inc.
BeiGene USA, Inc. Pharmaceuticals: MajorHealth Technology BeiGene USA, Inc. engages in pharmaceutical development. The company is headquartered in Cambridge, MA. | 1 jaar |
Patrick Rivers | M | - | 2 jaar | |
S. Michael Imperiale | M | - | 2 jaar | |
Kanya Rajangam | M | 50 | 3 jaar | |
Ronald Shazer | M | 56 | 2 jaar | |
Raju Mohan | M | 67 | 5 jaar | |
Natalie Sacks | M | 59 | 2 jaar | |
Qin Hua Ru | M | - | 1 jaar | |
Scott Brown | M | 43 | 2 jaar | |
Wally Reiher | M | - | 12 jaar | |
Jane M. Green | M | - | - | |
Anne Champsaur | M | - | - | |
Jeffrey R. Latts | M | 76 | 6 jaar | |
Erick E. Hanson | M | 77 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 10 jaar |
Steven B. Binion | M | 71 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
Lupe M. Rivera | F | 57 | 9 jaar | |
Timothy Walbert | M | 57 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 jaar |
Timothy Charles Melkus | M | 65 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 1 jaar |
J. Garland | M | 55 | 3 jaar | |
Frank Karbe | M | 55 | 10 jaar | |
Kristine Ball | M | 52 | 5 jaar | |
Frank C. Becker | M | 88 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 jaar |
Imran Ahmad | M | 59 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 6 jaar |
Shahid Ali | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 10 jaar |
Kaveh T. Safavi | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | - |
Paul Freiman | M | 89 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 jaar |
Jeffrey Sherman | M | 69 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 jaar |
Leone Patterson | F | 61 | 3 jaar | |
Steven James | M | 66 | 1 jaar | |
Angie You | M | 51 | - | |
Jerome Dvonch | M | 56 | 4 jaar | |
Arthur P. DeCillis | M | 68 | 8 jaar | |
Bernard A. Fox | M | - |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 7 jaar |
John N. Kapoor | M | 80 |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | 21 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 85 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Kirk Rosemark
- Persoonlijk netwerk